Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma
Standard
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. / Siegel, David; Weisel, Katja; Zahlten-Kumeli, Anita; Medhekar, Rohan; Ding, Bifeng; Leleu, Xavier.
in: LEUKEMIA LYMPHOMA, Jahrgang 62, Nr. 12, 12.2021, S. 3002-3010.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma
AU - Siegel, David
AU - Weisel, Katja
AU - Zahlten-Kumeli, Anita
AU - Medhekar, Rohan
AU - Ding, Bifeng
AU - Leleu, Xavier
PY - 2021/12
Y1 - 2021/12
N2 - CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). A secondary objective of CANDOR was to evaluate health-related quality of life (HRQoL) scores using the Global Health Status (GHS)/Quality of Life (QoL) domain of the EORTC QLQ-C30. Scores were compared between KdD and Kd using a restricted maximum likelihood-based mixed effects model for repeated measures. GHS/QoL completion rates were >81% for both arms. Higher GHS/QoL scores were observed with KdD versus Kd from Cycle 7-26. The overall least squares mean estimate (95% CI) of the difference between treatment arms was 0.06 (-2.39 to 2.50; p = 0.96). In an exploratory analysis, 55.5% in the KdD arm and 43.0% in the Kd arm improved ≥10 points in GHS/QoL score from baseline. HRQoL was maintained with KdD, consistent with superior clinical benefit observed with KdD versus Kd in patients with RRMM.
AB - CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). A secondary objective of CANDOR was to evaluate health-related quality of life (HRQoL) scores using the Global Health Status (GHS)/Quality of Life (QoL) domain of the EORTC QLQ-C30. Scores were compared between KdD and Kd using a restricted maximum likelihood-based mixed effects model for repeated measures. GHS/QoL completion rates were >81% for both arms. Higher GHS/QoL scores were observed with KdD versus Kd from Cycle 7-26. The overall least squares mean estimate (95% CI) of the difference between treatment arms was 0.06 (-2.39 to 2.50; p = 0.96). In an exploratory analysis, 55.5% in the KdD arm and 43.0% in the Kd arm improved ≥10 points in GHS/QoL score from baseline. HRQoL was maintained with KdD, consistent with superior clinical benefit observed with KdD versus Kd in patients with RRMM.
U2 - 10.1080/10428194.2021.1941927
DO - 10.1080/10428194.2021.1941927
M3 - SCORING: Journal article
C2 - 34180331
VL - 62
SP - 3002
EP - 3010
JO - LEUKEMIA LYMPHOMA
JF - LEUKEMIA LYMPHOMA
SN - 1042-8194
IS - 12
ER -